Wytwarzanie produktów leczniczych jest dla nas nie tylko kwestia wykonania pewnego procesu technologicznego, ale misją związaną z człowiekiem opartą na wysokim standardzie jakości, bezpieczeństwa i skuteczności leków.
Mamy aktywną i kluczową rolę w podnoszeniu standardów życia codziennego. Sprawiamy, że społeczeństwo jest lepiej poinformowane, zdrowsze, szczęśliwsze i bezpieczniejsze
Sofia, Bulgaria, June 19, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on June 18, 2025 the Company sold 14 132 (fourteen thousand one hundred thirty-two) repurchased own shares representing 0.01% of the share capital of the Company, at a total value of BGN 91 954.04 on the Bulgarian Stock Exchange, the average price per share was BGN 6.51.
Sofia, Bulgaria, June 18, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on June 17, 2025 the Company sold 18 000 (eighteen thousand) repurchased own shares representing 0.01% of the share capital of the Company, at a total value of BGN 117 998.44 on the Bulgarian Stock Exchange, the average price per share was BGN 6.56.
Sofia, Bulgaria, June 17, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on June 16, 2025 the Company sold 808 (eight hundred eight) repurchased own shares representing 0.0004% of the share capital of the Company, at a total value of BGN 5 332.80 on the Bulgarian Stock Exchange, the average price per share was BGN 6.60.
Sofia, Bulgaria, June 16, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on June 13, 2025 the Company sold 9 192 (nine thousand one hundred ninety-two) repurchased own shares representing 0.005% of the share capital of the Company, at a total value of BGN 61 941.92 on the Bulgarian Stock Exchange, the average price per share was BGN 6.74.